Compare PTCT & WING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | WING |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.9B |
| IPO Year | 2006 | 2015 |
| Metric | PTCT | WING |
|---|---|---|
| Price | $69.04 | $178.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 27 |
| Target Price | $80.65 | ★ $301.69 |
| AVG Volume (30 Days) | 733.3K | ★ 1.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.63% |
| EPS Growth | ★ 264.48 | 67.84 |
| EPS | ★ 7.78 | 6.21 |
| Revenue | $264,734,000.00 | ★ $696,853,000.00 |
| Revenue This Year | N/A | $17.20 |
| Revenue Next Year | $17.70 | $15.86 |
| P/E Ratio | ★ $8.75 | $30.87 |
| Revenue Growth | ★ 36.19 | 11.35 |
| 52 Week Low | $35.95 | $142.24 |
| 52 Week High | $87.50 | $388.14 |
| Indicator | PTCT | WING |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 44.07 |
| Support Level | $64.00 | $142.24 |
| Resistance Level | $69.23 | $267.86 |
| Average True Range (ATR) | 2.38 | 11.21 |
| MACD | -0.33 | 2.41 |
| Stochastic Oscillator | 25.12 | 31.39 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.